Patricia Coyle, MD

Dr Patricia Coyle from Stony Brook University Medical Center in New York highlights new data on disease-modifying therapies (DMTs) from the 8th Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.

Focusing on relapsing-remitting multiple sclerosis (RRMS), Dr Coyle discusses new research that further explores the efficacy and rebound effects of DMTs, 24 of which are approved in the United States for this patient population.

She reports on results from a database study comparing DMTs vs moderate-efficacy drugs and escalating treatment in the first-line setting, a cohort of pediatric patients receiving adult-approved teriflunomide, and an exploration of fingolimod rebound syndrome.

Patricia K. Coyle, MD, Professor, Interim Chair, Director, Multiple Sclerosis Comprehensive Care Center, Department of Neurology, Stony Brook University Medical Center, Stony Brook, New York

Dr Patricia Coyle from Stony Brook University Medical Center in New York highlights new data on disease-modifying therapies (DMTs) from the 8th Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.

Focusing on relapsing-remitting multiple sclerosis (RRMS), Dr Coyle discusses new research that further explores the efficacy and rebound effects of DMTs, 24 of which are approved in the United States for this patient population.

She reports on results from a database study comparing DMTs vs moderate-efficacy drugs and escalating treatment in the first-line setting, a cohort of pediatric patients receiving adult-approved teriflunomide, and an exploration of fingolimod rebound syndrome.

Patricia K. Coyle, MD, Professor, Interim Chair, Director, Multiple Sclerosis Comprehensive Care Center, Department of Neurology, Stony Brook University Medical Center, Stony Brook, New York

Dr Patricia Coyle from Stony Brook University Medical Center in New York highlights new data on disease-modifying therapies (DMTs) from the 8th Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.

Focusing on relapsing-remitting multiple sclerosis (RRMS), Dr Coyle discusses new research that further explores the efficacy and rebound effects of DMTs, 24 of which are approved in the United States for this patient population.

She reports on results from a database study comparing DMTs vs moderate-efficacy drugs and escalating treatment in the first-line setting, a cohort of pediatric patients receiving adult-approved teriflunomide, and an exploration of fingolimod rebound syndrome.

Patricia K. Coyle, MD, Professor, Interim Chair, Director, Multiple Sclerosis Comprehensive Care Center, Department of Neurology, Stony Brook University Medical Center, Stony Brook, New York

Promising imaging developments may soon improve clinicians' ability to diagnose and monitor the progression of multiple sclerosis (MS). Dr Patricia Coyle, director of the Multiple Sclerosis Comprehensive Care Center at Stony Brook University Medical Center, reports on findings presented at the 8th Joint ACTRIMS-ECTRIMS Conference, this year known as MSVirtual 2020.

Dr Coyle emphasizes the importance of appropriate diagnosis as well as the need to improve the misdiagnosis rate. Advanced monitoring techniques that can detect MS with more accuracy are key. 

She highlights exciting research in novel MRI markers, including central vein sign and paramagnetic rim sign (PRS). One study shows reliable methods for quantification of PRS, which is especially critical if this prognostic marker is to be adopted for clinical practice. 

Dr Coyle highlights other studies focused on techniques that help monitor the damage from progressing MS, including further analysis of optical coherence tomography. 
 

Patricia K. Coyle, MD, Professor, Interim Chair, Director, Multiple Sclerosis Comprehensive Care Center, Department of Neurology, Stony Brook University Medical Center, Stony Brook, New York

Promising imaging developments may soon improve clinicians' ability to diagnose and monitor the progression of multiple sclerosis (MS). Dr Patricia Coyle, director of the Multiple Sclerosis Comprehensive Care Center at Stony Brook University Medical Center, reports on findings presented at the 8th Joint ACTRIMS-ECTRIMS Conference, this year known as MSVirtual 2020.

Dr Coyle emphasizes the importance of appropriate diagnosis as well as the need to improve the misdiagnosis rate. Advanced monitoring techniques that can detect MS with more accuracy are key. 

She highlights exciting research in novel MRI markers, including central vein sign and paramagnetic rim sign (PRS). One study shows reliable methods for quantification of PRS, which is especially critical if this prognostic marker is to be adopted for clinical practice. 

Dr Coyle highlights other studies focused on techniques that help monitor the damage from progressing MS, including further analysis of optical coherence tomography. 
 

Patricia K. Coyle, MD, Professor, Interim Chair, Director, Multiple Sclerosis Comprehensive Care Center, Department of Neurology, Stony Brook University Medical Center, Stony Brook, New York

Promising imaging developments may soon improve clinicians' ability to diagnose and monitor the progression of multiple sclerosis (MS). Dr Patricia Coyle, director of the Multiple Sclerosis Comprehensive Care Center at Stony Brook University Medical Center, reports on findings presented at the 8th Joint ACTRIMS-ECTRIMS Conference, this year known as MSVirtual 2020.

Dr Coyle emphasizes the importance of appropriate diagnosis as well as the need to improve the misdiagnosis rate. Advanced monitoring techniques that can detect MS with more accuracy are key. 

She highlights exciting research in novel MRI markers, including central vein sign and paramagnetic rim sign (PRS). One study shows reliable methods for quantification of PRS, which is especially critical if this prognostic marker is to be adopted for clinical practice. 

Dr Coyle highlights other studies focused on techniques that help monitor the damage from progressing MS, including further analysis of optical coherence tomography. 
 

Patricia K. Coyle, MD, Professor, Interim Chair, Director, Multiple Sclerosis Comprehensive Care Center, Department of Neurology, Stony Brook University Medical Center, Stony Brook, New York